COMPANY:

Reveal Genomics

P=NA| N=459 | "REVEAL GENOMICS, S.L...announced today a new addition to its pipeline consisting of a novel biomarker approach in liquid biopsy for patients with advanced cancer....Firstly, REVEAL GENOMICS^®' proprietary machine-learning multi-gene signatures were applied in plasma and linked to DNA/RNA/protein data from tumor tissue (paired samples). The results showed, for the first time, that multi-gene signatures tracking complex biological features can be successfully identified in ctDNA. These complex biological features include, among others, measures of tumor proliferation and estrogen receptor signaling, similar to what is accomplished using direct tumor tissue DNA or RNA profiling....Secondly, the authors discovered that the combination of 150 biologically relevant signatures identified 4 new DNA-based molecular subtypes of breast cancer."

"REVEAL GENOMICS...announced positive results for HER2X® in a range of clinical scenarios, demonstrating the test’s reliability....The HER2DX pCR score predicted response to chemotherapy in combination with trastuzumab and pertuzumab in DAPHNe and GOM clinical trials....The results of 4 studies (APT, ATEMPT, DAPHNe and GOM) have been made public during the San Antonio Breast Cancer Symposium (SABCS), held from December 6 to 10 in San Antonio, Texas (USA)."

"REVEAL GENOMICS, S.L...announced another validation of HER2DX, the world's first specialized genomic test for HER2+ breast cancer....The APT clinical trial, published in the New England Journal of Medicine in 2015, demonstrated that a de-escalation treatment strategy based on weekly paclitaxel for 3 months and one year of trastuzumab (TH) is highly efficacious for patients with small node-negative HER2+ tumors. The ATEMPT clinical trial, published in the Journal of Clinical Oncology in 2021, demonstrated that 17 cycles of the anti-HER2 antibody drug-conjugate trastuzumab emtansine (T-DM1, Kadcyla, Roche) is highly effective for patients with stage 1 HER2+ breast cancer....In both trials, the HER2DX risk score was found to be significantly associated with relapse-free interval (RFI)....'The results of HER2DX in APT and ATEMPT are remarkable, and support the test's strong prognostic value in early-stage HER2+ breast cancer..."

"REVEAL GENOMICS, SL, a biotechnological start-up dedicated to revolutionizing precision oncology through innovation in biomarkers, has participated in two studies that have sought to demonstrate the clinical potential of HER2DX ®️ as well as its usefulness in therapeutic management of patients with early HER2+ cancer."

"The companies will cooperate to implement precision oncology in clinical trials with the aim of optimizing their design and developing new treatments...HER2DX®, the world's first specialized genomic test for HER2+ breast cancer and marketed by REVEALGENOMICS®, will be validated in the PHERGain and PHERGain-2 trials conducted by MEDSIR."

P2 | N=64 | "The data obtained from the analysis of tumor samples from the PerELISA phase II clinical trial showed that the HER2DX pCR-score and the HER2DX ERBB2-score predicted the probability of a patient responding to the triple-drug combination of trastuzumab, pertuzumab and letrozole, when given before surgery (i.e., the neoadjuvant setting). These findings in patients with newly diagnosed HER2+/hormone receptor positive (HER2+/HR+) breast cancer can help identify better who might benefit from dual HER2 blockade with trastuzumab and pertuzumab."

"Reveal Genomics...announced today a new collaborative project with the Dana-Farber Cancer Institute to evaluate the HER2DX® genomic test across three clinical trials (APT, ATEMPT, and DAPHNE) in early-stage HER2+ breast cancer...Today’s agreement represents a step forward in seeking more clinical evidence of the HER2DX® test to help personalize therapy in patients who have early-stage HER2+ breast cancer."

"Reveal Genomics...has launched its first genomic test. The HER2DX® test predicts the risk of HER2+ breast cancer recurrence in newly diagnosed patients and the likelihood that they will respond to pharmacological treatment. This innovative tool, which combines a patient's clinical data and the tumor's genomic profile, is the world's first specialized genomic test for HER2+ breast cancer."

"Researchers from Hospital Clínic-IDIBAPS-UB, VHIO, University of Padua (Italy) and REVEAL GENOMICS have developed and validated HER2DX, a genomic test that uses the clinical details and genomic data of early-stage HER2+ patients to predict their prognosis and probability to respond to drug therapies prior to undergoing surgery. HER2DX is the world's first genomic test intended for patients with HER2+ breast cancer...'Just one year after setting up REVEAL GENOMICS, we are happy to launch the company's first precision oncology test."